| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef1a63d62269b5b64f99ee8720351481 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1133 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20 |
| filingDate |
1988-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_870784d2acd3417f5c23646b2f3bf544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ecf88723d7734e9619193674ceb4eff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a05504a10f322622af7a6236f063a08a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6761d33eb4987edc61e15a54141f1318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3f4a6e61d93db759ceafc56e3775717 |
| publicationDate |
1988-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8808849-A1 |
| titleOfInvention |
Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
| abstract |
A process for recovering highly pure, recombinant IL-2 from transformed microorganisms in which the cells are disrupted; impure recombinant IL-2 is isolated in the form of refractile bodies from the disruptate; the impure IL-2 is dissolved and denatured with at least 6 M guanidine hydrochloride containing a reducing agent; the reduced IL-2 is precipitated and resolubilized; the reduced solubilized IL-2 therein is oxidized by a controlled oxidation in which the concentration of guanidine hydrochloride is maintained at least at 6 M; the oxidized IL-2 is refolded by reducing the concentration of guanidine hydrochloride in the solution; and the oxidized, refolded IL-2 is further purified by ion exchange chromatography or hydrophobic interaction chromatography and ion exchange chromatography. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5258496-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9704003-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5650494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5403915-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03097669-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7057016-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5410026-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5288931-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9200993-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5922846-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5756672-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5663304-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0337243-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6322779-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5808006-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5317092-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4929700-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03097669-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5661001-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5861150-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4931543-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9704003-A3 |
| priorityDate |
1987-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |